Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Pathways Reduce Care Variation and Cost of Care, Improve Overall Outcomes
By
Wayne Kuznar
Pathways
June 2015, Vol 6, No 5
Washington, DC—The establishment of pathways in oncology can reduce care variation and enhance value in patient care, said Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read More
Comprehensive Genomic Profiling Enables Efficient “N of 1” Trials
By
Wayne Kuznar
June 2015, Vol 6, No 5
Washington, DC—Genomically driven medicine has created an opportunity for value in oncology by substantially improving outcomes and quality of life for patients with advanced cancer, said Vincent A. Miller, MD, Chief Medical Officer, Foundation Medicine, Cambridge, MA, at the Fifth Annual Conference of the Association for ValueBased Cancer Care.
Read More
Value Propositions - June 2015
Value Propositions
,
Value Peer-spectives
June 2015, Vol 6, No 5
Read More
Efficacy and Safety of BCD-021, a Bevacizumab Biosimilar Candidate, Compared to Avastin® in Patients with Advanced Nonsquamous NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
,
Biosimilars
Conference Correspondent
Read More
Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read More
GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read More
ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read More
PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read More
First-line Monotherapy with Nivolumab in Advanced NSCLC: Safety, Efficacy, and Correlation of Outcomes with PD-L1 Expression
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read More
Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read More
Page 194 of 330
191
192
193
194
195
196
197
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma